课题基金 / 基金详情

Wearable Device for Prevention of Opioid-Induced Respiratory Depression, Hypoxemia and Death

Wearable Device for Prevention of Opioid-Induced Respiratory Depression, Hypoxemia and Death
用于预防阿片类药物引起的呼吸抑制、低氧血症和死亡的可穿戴设备
批准号:
10012569
负责人:
Lloyd Olson
金额:
$34.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-06-15 至 2021-06-30

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Significance: Opioids kill 250 persons daily in the US, mostly by respiratory arrest. Hypoxemia (low blood oxygen), typically precedes respiratory arrest. Timely detection and correction of hypoxemia saves lives. The Oxalert EPO is a wearable device designed to automatically restore breathing and reverse hypoxemia without human intervention. The Oxalert EPO (Enhanced Pulse Oximeter) is an FDA designated Breakthrough Device, (...more effective diagnosis or treatment for a life-threatening condition... for which no equivalent alternatives exist... in the best interests of patients.)24 The FDA recognizes our initial proposed Indication for Use in hospitalized post- operative patients receiving opioids. We intend to confirm feasibility both in-hospital and at home, in order to support a later FDA Indication for Use in patients at home using opioids. The Center for Medicare and Medicare Services (CMS) will now reimburse automatically for FDA-approved Breakthrough Devices. Preliminary Data: Zornow showed that automatic arousal was superior to 1:1 nursing care.17 Sessler incidentally verified the "Arousal Effect" in a study of 1200 post-op in-patients.16 Specific Aims: AIM1) Prove feasibility of the Oxalert arousal device for restoring breathing and reversing hypoxemia in post-operative patients receiving opioids. AIM2) Determine statistical scalability needs for future Phase II study. AIM3) Evaluate patient tolerance, nurse feedbacl and human factors/usability. AIM4) Compare the extent of nocturnal oxygen desatuations in home-use before and after surgery, with and without Oxalert interventions. Summary: Breakthrough Device status should facilitate FDA approval for the Oxalert EPO. Devices with a favorable Risk:Benefit ratio under the Twenty-First Cures Act qualify for less FDA emphasis on lengthy pre-market studies as opposed to post-market data in order to expedite patient access. We hope to find the shortest path to getting this device to all who might benefit.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Wearable device for prevention of postoperative and post-discharge hypoxemia: A randomized pilot trial.
用于预防术后和出院后低氧血症的可穿戴设备:一项随机试点试验。
DOI: 10.1111/aas.14193
发表时间: 2023
期刊: Acta anaesthesiologica Scandinavica
影响因子: 2.1
作者: [Li,Kai, Saab,Remie, Bravo,Mauro, Mascha,EdwardJ, Han,Yanyan, Nault,Rod, Olson,Lloyd, Sessler,DanielI]
通讯作者: Sessler,DanielI
海外基金